Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3582 Target Snapshot

Protein kinase C epsilon type · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,188Compounds
419Assays
4Approved Drugs
798.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein kinase C epsilon type shows clinical signal disease relevance led by pain. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q02156. Start with pain, then reuse UniProt Q02156 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with pain, then reuse UniProt Q02156 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
pain

Protein kinase C epsilon type shows clinical signal disease relevance led by pain. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with pain because it currently carries clinical signal support. Linked drugs include KAI-1678. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein kinase C epsilon type as ChEMBL target CHEMBL3582, mapped to UniProt Q02156. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein kinase C epsilon type
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3582
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q02156
Protein kinase C epsilon type
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Protein kinase C epsilon type is the right protein anchor across sources, using UniProt Q02156 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why pain is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameProtein kinase C epsilon type
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ02156
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProtein kinase C epsilon type
UniProt AccessionQ02156
Component TypeProtein
Sequence Length737 aa

Protein kinase C epsilon type

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Protein kinase C epsilon type, mapped to UniProt Q02156. Sequence length is 737 aa.

Mapped IDQ02156
Review nameProtein kinase C epsilon type
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Protein kinase C epsilon type shows clinical signal disease relevance led by pain. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
pain
1 linked drug · 1 direct · 1 efficacy
Linked drugKAI-1678
Clinical signal Phase II
postherpetic neuralgia
1 linked drug · 1 direct · 1 efficacy
Linked drugKAI-1678
Clinical signal Phase II
spinal cord injury
1 linked drug · 1 direct · 1 efficacy
Linked drugKAI-1678
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with pain because it currently carries clinical signal support. Linked drugs include KAI-1678. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasepain
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
10
Phase III
4
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50462.0
KI191.0
EC5011.0
KD134.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.85 IC50 0.143 Preclinical
CHEMBL27768 9.66 Kd 0.22 Preclinical
CHEMBL388978 9.6 Kd 0.25 Preclinical
CHEMBL337834 9.43 Kd 0.37 Preclinical
CHEMBL279115 9.35 Ki 0.45 Clinical
CHEMBL399981 9.33 Ki 0.47 Preclinical
CHEMBL337834 9.26 Ki 0.55 Preclinical
CHEMBL265998 9.24 Ki 0.58 Preclinical
CHEMBL2148106 9.2 Ki 0.63 Preclinical
CHEMBL2151411 9.15 IC50 0.7 Preclinical
Distribution

pChEMBL Value Distribution

70
5.0
36
5.5
67
6.0
79
6.5
88
7.0
83
7.5
68
8.0
22
8.5
17
9.0
6
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
RUXOLITINIB
CHEMBL1789941
Approved 2011
Properties Compare Identifier
Assay Landscape

Assay Landscape

419
Total Assays
486
Tested Compounds
3
Assay Types
Binding — 414 assays, 486 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 317 360 6.8
assay format 57 83 6.9
cell-based format 37 17 6.1
cell membrane format 2 26 7.7
subcellular format 1 0 —
Functional — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 4 0 —
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine